Search - tctmd.com

Displaying 1 - 20 of 38

Sort: Relevancy | Date

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

News Daily News

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Michael O'Riordan

June 25, 2025

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

News Daily News

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

May 16, 2025

Patchy Anticoagulation Use During COVID Pandemic Raises Questions

News Daily News

Patchy Anticoagulation Use During COVID Pandemic Raises Questions

March 06, 2025

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

News Daily News

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

December 04, 2024

Scientific Statement Reviews Current Antithrombotic Options in PAD

News Daily News

Scientific Statement Reviews Current Antithrombotic Options in PAD

August 26, 2024

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

August 19, 2024

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

News Daily News

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

March 15, 2024

Sepsis Emerges as Powerful CVD Risk Factor in Large US Analysis

News Daily News

Sepsis Emerges as Powerful CVD Risk Factor in Large US Analysis

February 02, 2023

Don’t Skimp on Anticoagulation in Isolated Distal DVT: RIDTS

News Daily News

Don’t Skimp on Anticoagulation in Isolated Distal DVT: RIDTS

December 01, 2022

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

News Daily News

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

June 29, 2022

Large Study Confirms Clot Risks With Oxford/AstraZeneca COVID-19 Vaccine

News Daily News

Large Study Confirms Clot Risks With Oxford/AstraZeneca COVID-19 Vaccine

June 15, 2022

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

News Daily News

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

January 20, 2022

FDA Approves Two Additional Indications for Rivaroxaban in Children

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

December 21, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

News Daily News

As CDC Moves to Update Contraception Guidance, Cardiologists Should Take Note

Alexandra Dangas

September 06, 2021

CVST Risk Far Lower With Viral-Vector Vaccines Than With COVID-19 Itself

News Daily News

CVST Risk Far Lower With Viral-Vector Vaccines Than With COVID-19 Itself

June 10, 2021

Observational Study Supports Continuing Oral Anticoagulation During PCI

News Daily News

Observational Study Supports Continuing Oral Anticoagulation During PCI

Michael O'Riordan

April 06, 2021

INSPIRATION: No Dip in COVID-19 Deaths or Thromboses With Higher Anticoagulation Dose

News Daily News

INSPIRATION: No Dip in COVID-19 Deaths or Thromboses With Higher Anticoagulation Dose

March 19, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.